A number of firms have modified their ratings and price targets on shares of vTv Therapeutics (NASDAQ: VTVT) recently:

  • 9/9/2017 – vTv Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $6.25 price target on the stock. According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
  • 9/7/2017 – vTv Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
  • 8/30/2017 – vTv Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $5.50 price target on the stock. According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
  • 8/26/2017 – vTv Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
  • 8/24/2017 – vTv Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $5.25 price target on the stock. According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
  • 8/19/2017 – vTv Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
  • 8/8/2017 – vTv Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “buy” rating. They now have a $4.75 price target on the stock. According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
  • 8/4/2017 – vTv Therapeutics was given a new $13.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 8/4/2017 – vTv Therapeutics had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $15.00 price target on the stock. They wrote, “We reiterate our BUY. Pivotal Ph3 azeliragon Alzheimer trials enrollment complete: Part A to deliver data in 1H18 and Part B in 2H. Mgmt. announced Ph3 STEADFAST Part B completed enrollment, including 20-25% ROW pts. Conducted under Special Protocol Assessment, STEADFAST is an 18-month, randomized, double-blind, placebo-controlled study assessing oral, once- daily azeliragon’s effect on cognitive/functional decline in 400 mild Alzheimer’s Disease (AD) pts. on standard-of-care (SOC; acetylcholinesterase inhibitor and/or memantine). Co-primary endpoints include change in AD Assessment Scale-cognitive subscale (ADAS- Cog11) and Clinical Dementia Rating Scale Sum of Boxes (CDR-sb). Part A completed enrollment in mid-16. In a Ph2b trial assessing SOC +/- 5mg azeliragon at 18 months, daily azeliragon was well-tolerated and had significantly lower ADAS-Cog11 and CDR-sb score decline, with greater benefit in mild patients, and significantly fewer psychiatric events.””

vTv Therapeutics Inc. (NASDAQ VTVT) traded down 0.18% on Wednesday, reaching $5.42. 8,722 shares of the company traded hands. The firm’s market cap is $52.54 million. The stock has a 50-day moving average price of $5.51 and a 200-day moving average price of $5.90. vTv Therapeutics Inc. has a 52-week low of $4.65 and a 52-week high of $7.50.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.02. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.19 million. Analysts anticipate that vTv Therapeutics Inc. will post ($1.06) earnings per share for the current fiscal year.

In other vTv Therapeutics news, major shareholder Ronald O. Perelman acquired 20,000 shares of the business’s stock in a transaction on Tuesday, August 22nd. The stock was purchased at an average price of $4.57 per share, with a total value of $91,400.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Ronald O. Perelman acquired 85,000 shares of the business’s stock in a transaction on Friday, August 11th. The stock was acquired at an average cost of $4.13 per share, with a total value of $351,050.00. The disclosure for this purchase can be found here. Insiders acquired a total of 165,000 shares of company stock valued at $728,150 in the last three months. Insiders own 0.80% of the company’s stock.

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Receive News & Stock Ratings for vTv Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc and related stocks with our FREE daily email newsletter.